RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial

Area of Science:

• Rheumatology
• Osteoarthritis Research
• Clinical Trials

Background:

• Erosive hand osteoarthritis (OA) is a debilitating condition with limited therapeutic options.
• Current treatments primarily focus on symptom management rather than disease modification.

Purpose of the Study:

• To evaluate the structure-modifying effects of denosumab in patients with erosive hand OA.
• To assess denosumab's impact on radiographic progression and new bone erosion formation.

Main Methods:

• A monocentric, placebo-controlled, double-blind, randomized phase 2a clinical trial.
• 51 patients received denosumab (60 mg every 3 months) and 49 received placebo for 48 weeks.
• Radiographic changes were assessed using the Ghent University Scoring System (GUSS) and anatomical phase scoring.

Main Results:

• Denosumab significantly improved GUSS scores at weeks 24 and 48, indicating joint remodeling.
• The denosumab group showed a significant reduction in the development of new erosive joints compared to placebo.
• Fewer adverse events were reported in the denosumab group than in the placebo group.

Conclusions:

• Denosumab exhibits structure-modifying properties in erosive hand OA.
• The drug effectively induces joint remodeling and prevents the progression of new erosive lesions.
• Denosumab represents a promising therapeutic agent for managing erosive hand OA.